Pulse Biosciences Inc
Last updated September 27, 2026
Organization details
- Legal name
- Pulse Biosciences Inc
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- PLSE
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001625101
Board of directors
-
Burke Thomas Barrett · Director · President and CEOSince 2024
-
Darrin Uecker · Director · Chief Technology OfficerSince 2023
-
Den Broek Richard Van · DirectorSince 2023
-
Mahkam Zanganeh · DirectorSince 2023
-
Manmeet Singh Soni · DirectorSince 2023
-
Maria Sainz · DirectorSince 2026
-
Mitchell E. Levinson · Director · Chief Strategy OfficerSince 2023
-
Paul A. Laviolette · Director · Chief Executive OfficerSince 2024
-
Robert W. Duggan · DirectorSince 2023
-
Shelley D. Spray · DirectorSince 2023
Chief executives
Paul A. Laviolette
· Chief Executive Officer
Dates unknown
Burke Thomas Barrett
· President and CEO
Since May 2024
Board connections
6 of this board's directors also sit on 4 other boards.
- via Mahkam Zanganeh, Manmeet Singh Soni and Robert W. Duggan
- via Den Broek Richard Van
- via Paul A. Laviolette
- via Maria Sainz
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $13,295,338
- 2 purchases by 2 insiders
- Sold, last 12 months
- $3,017,438
- 8 sales by 1 insider
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| May 11, 2026 | Paul A. Laviolette Director, Officer (Chief Executive Officer) | Open-market purchase | +15,000 | $19.69 | $295,350 |
| May 11, 2026 | Robert W. Duggan Director, 10% owner | Open-market purchase | +660,233 | $19.69 | $12,999,988 |
| Feb 18, 2026 | Danahy Kevin Patrick Officer (Chief Commercial Officer) | Option exercise | +5,000 | $1.53 | $7,650 |
| Feb 18, 2026 | Danahy Kevin Patrick Officer (Chief Commercial Officer) | Open-market sale | −5,000 | $23.64 | $118,200 |
| Feb 17, 2026 | Danahy Kevin Patrick Officer (Chief Commercial Officer) | Option exercise | +20,000 | $1.53 | $30,600 |
| Feb 17, 2026 | Danahy Kevin Patrick Officer (Chief Commercial Officer) | Open-market sale | −20,000 | $23.63 | $472,600 |
| Feb 13, 2026 | Danahy Kevin Patrick Officer (Chief Commercial Officer) | Option exercise | +20,000 | $1.53 | $30,600 |
| Feb 13, 2026 | Danahy Kevin Patrick Officer (Chief Commercial Officer) | Open-market sale | −20,000 | $23.53 | $470,600 |
| Feb 12, 2026 | Danahy Kevin Patrick Officer (Chief Commercial Officer) | Option exercise | +20,000 | $1.53 | $30,600 |
| Feb 12, 2026 | Danahy Kevin Patrick Officer (Chief Commercial Officer) | Open-market sale | −20,000 | $23.37 | $467,400 |
| Feb 11, 2026 | Danahy Kevin Patrick Officer (Chief Commercial Officer) | Option exercise | +20,000 | $1.53 | $30,600 |
| Feb 11, 2026 | Danahy Kevin Patrick Officer (Chief Commercial Officer) | Open-market sale | −20,000 | $25.20 | $504,000 |
| Feb 10, 2026 | Danahy Kevin Patrick Officer (Chief Commercial Officer) | Option exercise | +20,000 | $1.53 | $30,600 |
| Feb 10, 2026 | Danahy Kevin Patrick Officer (Chief Commercial Officer) | Open-market sale | −20,000 | $23.52 | $470,400 |
| Feb 9, 2026 | Danahy Kevin Patrick Officer (Chief Commercial Officer) | Option exercise | +20,000 | $1.53 | $30,600 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.